Stock Screener App

無料 -

インストール

4.2949

4.98% -0.2251

Perspective Therapeutics Inc (CATX)

概要ニュース株価時系列ディスカッション予測株式分割

Perspective Therapeutics Inc (CATX) 最新ニュース

Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat

Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn

H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa

CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus

H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com

Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat

PERSPECTIVE THERAPEUTICS INC (CATX) Fundamental Analysis & Valuation - ChartMill

Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - marketscreener.com

Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail

If You Invested $1,000 in Perspective Therapeutics Inc (CATX) - Stock Titan

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M - MarketBeat

Jones Trading reiterates Perspective Therapeutics stock Buy rating By Investing.com - Investing.com India

Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail

Jones Trading reiterates Perspective Therapeutics stock Buy rating - Investing.com

Perspective Therapeutics (CATX) Receives Analyst Rating Boost | CATX Stock News - GuruFocus

B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price - MarketBeat

Perspective Therapeutics (CATX) Receives Analyst Rating Boost | - GuruFocus

Perspective Therapeutics (CATX) Receives Boost from UBS with Rai - GuruFocus

Perspective Therapeutics price target raised to $13 from $11 at B. Riley - TipRanks

UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating - marketscreener.com

UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock - MarketBeat

Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C - GuruFocus

Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush - MarketBeat

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail

B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating - marketscreener.com

Perspective Therapeutics (CATX) to Release Earnings on Wednesday - MarketBeat

RBC cuts Perspective Therapeutics stock price target on model updates By Investing.com - Investing.com Australia

Perspective Therapeutics Q4 2025 earnings preview - MSN

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 - The Manila Times

Truist reiterates Buy on Perspective Therapeutics stock By Investing.com - Investing.com Canada

BTIG Reiterates Buy Rating for CATX with $14 Price Target | CATX Stock News - GuruFocus

Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00 - MarketBeat

RBC Capital Lowers Price Target for CATX While Maintaining 'Outp - GuruFocus

Truist reiterates Buy on Perspective Therapeutics stock - Investing.com

RBC cuts Perspective Therapeutics stock price target on model updates - Investing.com

Perspective Therapeutics stock rating reiterated at Buy by BTIG - Investing.com South Africa

Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform By Investing.com - Investing.com South Africa

Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform - Investing.com

Perspective Therapeutics (NYSEAMERICAN:CATX) Receives "Buy" Rating from BTIG Research - MarketBeat

RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk - marketscreener.com

Perspective Therapeutics, Inc. 2025 10-K Report: Advancing Targeted Alpha Therapy Radiopharmaceuticals for Cancer Treatment - Minichart

Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 4.4%Here's What Happened - MarketBeat

Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026 - Bitget

Perspective Therapeutics earnings missed by $0.16, revenue fell short of estimates - Investing.com Canada

Perspective Therapeutics Reports 2025 Results, Highlights Pipeline Progress - TipRanks

Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Perspective Therapeutics (NYSE: CATX) expands targeted alpha cancer pipeline - Stock Titan

CATX: Clinical pipeline advances with strong safety, efficacy, and funding to support growth into 2027 - TradingView

Perspective Therapeutics (NYSE: CATX) details 2025 loss and cash runway to 2027 - Stock Titan

BRIEF-Perspective Therapeutics FY EPS USD -1.4 - TradingView

ZBH

$89.04

1.60%

STE

$225.49

1.02%

DXCM

$66.88

0.00%

PHG

$27.43

0.05%

GEHC

$72.17

0.29%

EW

$83.47

0.97%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | ロイターで開く